{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T11:05:23Z","timestamp":1770894323974,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:00:00Z","timestamp":1680912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jbo.2023.100478","type":"journal-article","created":{"date-parts":[[2023,4,10]],"date-time":"2023-04-10T15:44:52Z","timestamp":1681141492000},"page":"100478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents"],"prefix":"10.1016","volume":"40","author":[{"given":"Tomoaki","family":"Fukui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keisuke","family":"Oe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teruya","family":"Kawamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Iwakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuo","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takafumi","family":"Hiranaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryosuke","family":"Kuroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Niikura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6024","key":"10.1016\/j.jbo.2023.100478_b0005","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1126\/science.1203543","article-title":"A perspective on cancer cell metastasis","volume":"331","author":"Chaffer","year":"2011","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.jbo.2023.100478_b0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ctrv.2010.04.003","article-title":"Metastasis and bone loss: advancing treatment and prevention","volume":"36","author":"Coleman","year":"2010","journal-title":"Cancer Treat. Rev."},{"issue":"16","key":"10.1016\/j.jbo.2023.100478_b0015","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jbo.2023.100478_b0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.jbo.2023.100478_b0025","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"issue":"4","key":"10.1016\/j.jbo.2023.100478_b0030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1634\/theoncologist.2014-0328","article-title":"Systematic literature review and network meta-analysis comparing bone-targeted agents for the prevention of skeletal-related events in cancer patients with bone metastasis","volume":"20","author":"Wang","year":"2015","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.jbo.2023.100478_b0035","doi-asserted-by":"crossref","first-page":"350","DOI":"10.4048\/jbc.2014.17.4.350","article-title":"Survival benefit of zoledronic Acid in postmenopausal breast cancer patients receiving aromatase inhibitors","volume":"17","author":"Ahn","year":"2014","journal-title":"J. Breast Cancer"},{"issue":"17","key":"10.1016\/j.jbo.2023.100478_b0040","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/1078-0432.CCR-11-3310","article-title":"Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid","volume":"18","author":"Martin","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jbo.2023.100478_b0045","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"2","author":"Wong","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"issue":"22","key":"10.1016\/j.jbo.2023.100478_b0050","first-page":"2189","article-title":"Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. Reply","volume":"383","author":"Black","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.jbo.2023.100478_b0055","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/jbmr.1719","article-title":"Incidence of atypical nontraumatic diaphyseal fractures of the femur","volume":"27","author":"Dell","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"8","key":"10.1016\/j.jbo.2023.100478_b0060","doi-asserted-by":"crossref","first-page":"e10515","DOI":"10.1002\/jbm4.10515","article-title":"Incidence of Atypical Femoral Fracture and Its Mortality in a Single Center in Singapore","volume":"5","author":"Gani","year":"2021","journal-title":"JBMR Plus"},{"issue":"12","key":"10.1016\/j.jbo.2023.100478_b0065","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMc0707493","article-title":"Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate","volume":"358","author":"Lenart","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.jbo.2023.100478_b0070","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.jbo.2023.100478_b0075","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1007\/s00198-008-0805-x","article-title":"Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study","volume":"20","author":"Lenart","year":"2009","journal-title":"Osteoporos Int."},{"issue":"12","key":"10.1016\/j.jbo.2023.100478_b0080","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1001\/archinternmed.2012.1796","article-title":"Increasing occurrence of atypical femoral fractures associated with bisphosphonate use","volume":"172","author":"Meier","year":"2012","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.jbo.2023.100478_b0085","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00774-014-0606-6","article-title":"Atypical femoral fracture in a patient treated with denosumab","volume":"33","author":"Khow","year":"2015","journal-title":"J. Bone Miner. Metab."},{"issue":"6","key":"10.1016\/j.jbo.2023.100478_b0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/RLU.0000000000001592","article-title":"Impending Atypical Femoral Fracture in Patients With Medullary Thyroid Cancer With Skeletal Metastasis Treated With Long-term Bisphosphonate and Denosumab","volume":"42","author":"Koizumi","year":"2017","journal-title":"Clin. Nucl. Med."},{"issue":"3","key":"10.1016\/j.jbo.2023.100478_b0095","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.4158\/EP12367.CR","article-title":"A case of an unusual subtrochanteric fracture in a patient receiving denosumab","volume":"19","author":"Paparodis","year":"2013","journal-title":"Endocr. Pract."},{"key":"10.1016\/j.jbo.2023.100478_b0100","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.12.027","article-title":"Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report","volume":"61","author":"Thompson","year":"2014","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.jbo.2023.100478_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jbmr.1998","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research","volume":"29","author":"Shane","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2023.100478_b0110","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","article-title":"Intraclass correlations: uses in assessing rater reliability","volume":"86","author":"Shrout","year":"1979","journal-title":"Psychol. Bull."},{"issue":"3","key":"10.1016\/j.jbo.2023.100478_b0115","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.bone.2012.05.010","article-title":"Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy","volume":"51","author":"Chang","year":"2012","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.jbo.2023.100478_b0120","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/jbmr.2818","article-title":"Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience","volume":"31","author":"Edwards","year":"2016","journal-title":"J. Bone Miner. Res."},{"issue":"13","key":"10.1016\/j.jbo.2023.100478_b0125","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2106\/JBJS.J.01199","article-title":"Atypical subtrochanteric femoral fractures in patients with skeletal malignant involvement treated with intravenous bisphosphonates","volume":"93","author":"Puhaindran","year":"2011","journal-title":"J. Bone Joint Surg. Am."},{"issue":"1","key":"10.1016\/j.jbo.2023.100478_b0130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1186\/s12885-019-6236-6","article-title":"Atypical femoral fracture in patients with bone metastasis receiving denosumab therapy: a retrospective study and systematic review","volume":"19","author":"Takahashi","year":"2019","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jbo.2023.100478_b0135","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1634\/theoncologist.2016-0192","article-title":"Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy","volume":"22","author":"Yang","year":"2017","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.jbo.2023.100478_b0140","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"11","key":"10.1016\/j.jbo.2023.100478_b0145","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","article-title":"Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research","volume":"25","author":"Shane","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2023.100478_b0150","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jbo.2023.100478_b0155","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.08.019","article-title":"REaCT investigators, A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer","volume":"142","author":"Clemons","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.jbo.2023.100478_b0160","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.jbo.2023.100478_b0165","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2016.6316","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi","year":"2017","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.jbo.2023.100478_b0170","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.bone.2012.10.006","article-title":"Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy","volume":"52","author":"Chiang","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2023.100478_b0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1756-0500-6-11","article-title":"Discontinuation of alendronate and administration of bone-forming agents after surgical nailing may promote union of atypical femoral fractures in patients on long-term alendronate therapy","volume":"6","author":"Lin","year":"2013","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.jbo.2023.100478_b0180","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1359\/jbmr.090731","article-title":"Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures","volume":"25","author":"Aspenberg","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jbo.2023.100478_b0185","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.injury.2019.06.002","article-title":"Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures","volume":"50","author":"Kim","year":"2019","journal-title":"Injury"},{"key":"10.1016\/j.jbo.2023.100478_b0190","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2106\/JBJS.J.01379","article-title":"Parathyroid hormone 1\u201384 accelerates fracture-healing in pubic bones of elderly osteoporotic women","volume":"93","author":"Peichl","year":"2011","journal-title":"J. Bone Joint Surg. Am."},{"key":"10.1016\/j.jbo.2023.100478_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100416","article-title":"Experience with denosumab (XGEVA(R)) for prevention of skeletal-related events in the 10 years after approval","volume":"33","author":"Cadieux","year":"2022","journal-title":"J. Bone Oncol."},{"issue":"8","key":"10.1016\/j.jbo.2023.100478_b0200","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.jbo.2023.100478_b0205","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/BOT.0000000000000516","article-title":"Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter Retrospective Cohort","volume":"30","author":"Bogdan","year":"2016","journal-title":"J. Orthop. Trauma"},{"issue":"3","key":"10.1016\/j.jbo.2023.100478_b0210","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1302\/0301-620X.99B3.BJJ-2016-0276.R2","article-title":"Atypical femoral fractures related to bisphosphonate treatment: issues and controversies related to their surgical management","volume":"99-B","author":"Koh","year":"2017","journal-title":"Bone Joint J"}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137423000118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137423000118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,14]],"date-time":"2023-08-14T06:18:54Z","timestamp":1691993934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137423000118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":42,"alternative-id":["S2212137423000118"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2023.100478","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2023.100478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"100478"}}